Ablation of atrial arrhythmias in heart failure

Philip Aagaard; Luigi Di Biase; Andrea Natale

doi:10.1016/j.hfc.2014.12.008

Ablation of atrial arrhythmias in heart failure

Philip Aagaard, Luigi Di Biase, Andrea Natale

Medicine

Research output: Contribution to journal › Review article › peer-review

3 Scopus citations

Abstract

HF and AF are on the rise and often coexist. Pharmacologic rhythm control has not been shown to improve outcomes compared with pharmacologic rate control. It is possible that the benefits of maintaining SR are offset by the adverse effects of AADs. Catheter ablation of AF offers an opportunity to achieve SR without the downside of AADs. Several studies have shown that AF ablation improves prognostic markers, including ventricular function, exercise tolerance, and perceived quality of life in HF patients. Studies addressing the impact of this treatment strategy on cardiovascular outcomes and cost-effectiveness are ongoing.

Original language	English (US)
Pages (from-to)	305-317
Number of pages	13
Journal	Heart Failure Clinics
Volume	11
Issue number	2
DOIs	https://doi.org/10.1016/j.hfc.2014.12.008
State	Published - Apr 1 2015

Keywords

Antiarrhythmic drugs
Atrial arrhythmia
Atrial fibrillation
Atrial fibrillation ablation
Heart failure
Rate control
Rhythm control

ASJC Scopus subject areas

Cardiology and Cardiovascular Medicine

Access to Document

10.1016/j.hfc.2014.12.008

Cite this

@article{19626d88f4ed4e4bb83fa94391f4e831,

title = "Ablation of atrial arrhythmias in heart failure",

abstract = "HF and AF are on the rise and often coexist. Pharmacologic rhythm control has not been shown to improve outcomes compared with pharmacologic rate control. It is possible that the benefits of maintaining SR are offset by the adverse effects of AADs. Catheter ablation of AF offers an opportunity to achieve SR without the downside of AADs. Several studies have shown that AF ablation improves prognostic markers, including ventricular function, exercise tolerance, and perceived quality of life in HF patients. Studies addressing the impact of this treatment strategy on cardiovascular outcomes and cost-effectiveness are ongoing.",

keywords = "Antiarrhythmic drugs, Atrial arrhythmia, Atrial fibrillation, Atrial fibrillation ablation, Heart failure, Rate control, Rhythm control",

author = "Philip Aagaard and {Di Biase}, Luigi and Andrea Natale",

note = "Publisher Copyright: {\textcopyright} 2015 Elsevier Inc.",

year = "2015",

month = apr,

day = "1",

doi = "10.1016/j.hfc.2014.12.008",

language = "English (US)",

volume = "11",

pages = "305--317",

journal = "Heart Failure Clinics",

issn = "1551-7136",

publisher = "Elsevier Inc.",

number = "2",

}

TY - JOUR

T1 - Ablation of atrial arrhythmias in heart failure

AU - Aagaard, Philip

AU - Di Biase, Luigi

AU - Natale, Andrea

PY - 2015/4/1

Y1 - 2015/4/1

N2 - HF and AF are on the rise and often coexist. Pharmacologic rhythm control has not been shown to improve outcomes compared with pharmacologic rate control. It is possible that the benefits of maintaining SR are offset by the adverse effects of AADs. Catheter ablation of AF offers an opportunity to achieve SR without the downside of AADs. Several studies have shown that AF ablation improves prognostic markers, including ventricular function, exercise tolerance, and perceived quality of life in HF patients. Studies addressing the impact of this treatment strategy on cardiovascular outcomes and cost-effectiveness are ongoing.

AB - HF and AF are on the rise and often coexist. Pharmacologic rhythm control has not been shown to improve outcomes compared with pharmacologic rate control. It is possible that the benefits of maintaining SR are offset by the adverse effects of AADs. Catheter ablation of AF offers an opportunity to achieve SR without the downside of AADs. Several studies have shown that AF ablation improves prognostic markers, including ventricular function, exercise tolerance, and perceived quality of life in HF patients. Studies addressing the impact of this treatment strategy on cardiovascular outcomes and cost-effectiveness are ongoing.

KW - Antiarrhythmic drugs

KW - Atrial arrhythmia

KW - Atrial fibrillation

KW - Atrial fibrillation ablation

KW - Heart failure

KW - Rate control

KW - Rhythm control

UR - http://www.scopus.com/inward/record.url?scp=84926102110&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84926102110&partnerID=8YFLogxK

U2 - 10.1016/j.hfc.2014.12.008

DO - 10.1016/j.hfc.2014.12.008

M3 - Review article

C2 - 25834977

AN - SCOPUS:84926102110

SN - 1551-7136

VL - 11

SP - 305

EP - 317

JO - Heart Failure Clinics

JF - Heart Failure Clinics

IS - 2

ER -

Ablation of atrial arrhythmias in heart failure

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this